Covid-19 roundup: Pfiz­er/BioN­Tech vac­cine on verge of EU au­tho­riza­tion; Cure­Vac launch­es PhI­II tri­al in health­care ...

5 years ago
Coronavirus

Fol­low­ing a quick ap­proval in AML, Astel­las' Xospa­ta flops in chemo com­bo for front­line pa­tients

5 years ago
R&D

Patrick Soon-Sh­iong merges trou­bled 'moon shot' Nan­tK­west and cell ther­a­py play Im­mu­ni­ty­Bio in late-stage ex­pan­sion

5 years ago
Deals
Cell/Gene Tx

The FDA slaps a hold on uniQure's he­mo­phil­ia B gene ther­a­py as re­searchers ex­plore a case of liv­er can­cer in lat­est ...

5 years ago
FDA+

Go­ing head-to-head with Eylea, Roche touts PhI­II win for bis­pe­cif­ic block­buster con­tender in di­a­bet­ic mac­u­lar ede­ma

5 years ago
R&D

Best-sell­ing Tagris­so fur­ther out­paces an up­com­ing J&J ri­val, win­ning ap­proval in new NSCLC in­di­ca­tion

5 years ago
FDA+

Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing

5 years ago
Deals

Col­orec­tal drug can­di­dates fo­cal point of new col­lab­o­ra­tion be­tween Servi­er, Cel­sius Ther­a­peu­tics

5 years ago
Deals

Glax­o­SmithK­line joins So­sei's who's-who list of clients with glob­al li­cens­ing pact for IBD small mol­e­cules

5 years ago
Deals

It's a big day for Mod­er­na — and the world — as the FDA stamps an EUA on their vac­cine. And there are some ...

5 years ago
Bioregnum
FDA+

FDA un­ex­pect­ed­ly de­lays roxa de­ci­sion, foil­ing Fi­bro­Gen's Feb­ru­ary roll­out plans

5 years ago
FDA+

FDA stiff arms No­var­tis in a sur­prise set­back for their PC­SK9 drug in­clisir­an

5 years ago
FDA+
Manufacturing

In ground­break­ing move, FDA ap­proves My­ovan­t's re­l­u­golix as the first once-a-day pill for ad­vanced prostate can­cer

5 years ago
FDA+

News brief­ing: Bio­gen set­tles False Claims Act dis­pute for $22M; Lantern Phar­ma, Johns Hop­kins join forces to ad­vance ...

5 years ago
News Briefing

Im­mune Reg­u­la­tion makes Pe­ter Green­leaf chair­man and as­sem­bles a quin­tet of new ex­ecs; Bob Cough­lin moves on from ...

5 years ago
Peer Review

For­mer J&J VP sues phar­ma gi­ant for discim­i­na­tion and ha­rass­ment, ac­cus­es top ex­ecs — in­clud­ing Alex Gorsky — of ...

5 years ago
People

Ul­tragenyx bets up to $304M on an old No­var­tis drug for an ul­tra-rare bone dis­ease

5 years ago
Deals

Taysha Gene Ther­a­pies looks to build on rapid IPO with $85M dev-man­u­fac­tur­ing plant in North Car­oli­na

5 years ago
Startups
Manufacturing

Bio­science in­dus­try stake­hold­er col­lab­o­ra­tion key to ad­dress­ing in­equal­i­ty

5 years ago
Biotech Voices

Glax­o­SmithK­line makes big down pay­ment on biotech tar­get­ing 'syn­thet­ic vi­a­bil­i­ty' with start­up fund­ing, pipeline ...

5 years ago
Financing
Discovery

John Con­nol­ly has a new mis­sion to tack on to his role at the Park­er In­sti­tute: in­ter­im chief of a buzzy biotech ...

5 years ago
Bioregnum
Opinion

Mer­ck­'s Roger Perl­mut­ter con­tin­ues spin­ning deals, putting up $1B+ for Janux Ther­a­peu­tics and its T cell en­gagers

5 years ago
Deals

Covid-19 roundup: EU opts in­to 80M more Mod­er­na vac­cine dos­es; Boehringer In­gel­heim takes its an­ti­bod­ies in­to the ...

5 years ago
Coronavirus

No­var­tis' biotech part­ner ad­mits PhI­II Covid-19 de­feat for stem cell ther­a­py, trig­ger­ing ex­ten­sion of $1.2B+ deal ...

5 years ago
R&D
Coronavirus
First page Previous page 763764765766767768769 Next page Last page
A service from the Financial Times